pharma · Mantle Cell Lymphoma · Colon cancer
Telethon Foundation
Fondazione Telethon ETS
Fondazione Telethon ETS is a pharma organization headquartered in EU. Primary therapeutic focus areas include Mantle Cell Lymphoma, Colon cancer, colorectal cancer, NSCLC non-small cell lung cancer, Follicular lymphoma.
Company details
- Status
- Public
- HQ
- roma, IT
- Founded
- 1990
- Employees
- 343
- Programs
- 162
- Drugs
- 285
- Patents
- 0
ELACESTRANT
Phase 2 · small molecule · Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III)
ELACESTRANT for Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III) is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Internal code HELP Trial
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Fondazione Telethon ETS
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Patients with HR-positive, HER2-negative, non-metastatic node positive BC eligible for neoadjuvant treatment (clinical stage II-III)
- Status
- active
- Trials
- 1